[Ocular complications after treatment with intravenous cidofovir for cytomegalovirus retinitis].
OBJECTIVE
To describe the ocular changes observed in six patients treated with intravenous cidofovir for cytomegalovirus retinitis.


METHODS
We have studied six patients (12 eyes) treated with intravenous cidofovir. A complete ophthalmologic examination was performed before and after each dose during the follow-up period, paying special attention to intraocular pressure changes.


RESULTS
Three cases of non-granulomatous anterior uveitis with good response to conventional treatment were detected. The intraocular pressure decreased after the administration of the two first doses of the drug (p<0.01), and was followed by stabilization of the intraocular pressure with the next doses. In two of the eyes (16.7%), the decrease in the intraocular pressure was more than 50% in comparison to the measurements at the onset of treatment. In three eyes (18.7%), we detected acute anterior uveitis, which responded well to conventional treatment.


CONCLUSIONS
The intravenous administration of cidofovir for the treatment of cytomegalovirus retinitis is associated with important ocular changes that must be carefully observed in the follow-up of these patients.
Martínez de la Casa
J M
JM
Hospital Clínico Universitario San Carlos, Madrid, España. martinezcasa@lazzfree.com
Matilla Rodero
M
M
Castillo
A
A
García Feijoó
J
J
García Sánchez
J
J
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000821:virology; D000208:Acute Disease; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000077404:Cidofovir; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy*; D003596:Cytosine / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D015814:Ocular Hypotension / Q000139:chemically induced*; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D014606:Uveitis, Anterior / Q000139:chemically induced*
D000998:Antiviral Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D003596:Cytosine; D000077404:Cidofovir